Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · SPRUCE BIOSCIENCES, INC. (SPRB)

Spruce Biosciences Q2 net loss widens to $16.2 million from $2.1 million a year earlier

Negative Impact 4 of 5 earnings Written later

Spruce Biosciences reported second-quarter 2026 results with a net loss of $16.2 million, or $(6.68) per share, compared with a net loss of $2.1 million in the second quarter of 2025. The company said it expects its cash to fund operations and debt obligations into the second half of 2027, and it reiterated plans for a BLA submission for TA-ERT in the fourth quarter of 2026.

Key points

  • Q2 2026 net loss was $16.2 million, or $(6.68) per share, versus $2.1 million in Q2 2025.
  • Research and development expenses were $12.2 million in Q2 2026, driven by TA-ERT manufacturing scale-up and clinical development.
  • Cash and cash equivalents were $96.3 million as of June 30, 2026, up from $48.9 million at December 31, 2025.
  • Dr. Adrian Quartel was appointed Chief Medical Officer effective July 27, 2026.

The filing

CompanySPRUCE BIOSCIENCES, INC. (SPRB)
Form8-K, current report
Filed with the SECAug 12, 2026, 9:05 AM ET
Accession number0001193125-26-345874

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.